A tale of 2 pneumococcal vaccines

Clinical Infectious Diseases

Volumn 58, Issue 7, 2014, Pages 925-927

  Klugman, Keith P ^a  

^a BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Conjugate vaccine; Empyema; Pneumococcus; Pneumonia; Polysaccharide vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; PREVENAR13;

CLINICAL EFFECTIVENESS; COMMUNITY ACQUIRED PNEUMONIA; DRUG SURVEILLANCE PROGRAM; EMPYEMA; HUMAN; INFECTION PREVENTION; NOTE; OBSERVATIONAL STUDY; PLEURA EFFUSION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; VACCINATION; VACCINE FAILURE; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; MALE; PNEUMONIA, PNEUMOCOCCAL;

COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL;

EID: 84901404695     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu007     Document Type: Note

References (10)

1. Angoulvant F, Levy C, Grimprel E, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis 2014; 58:918-24.
2. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:203-7.
3. Madhi SA, Klugman KP; Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10:811-3.
4. Weinberger DM, Simonsen L, Jordan R, Steiner C, Miller M, Viboud C. Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. J Infect Dis 2012; 205:458-65.
5. Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014; 58:909-17.
6. Tessmer A, Welte T, Schmidt-Ott R, et al., CAPNETZ Study Group. Influenza vaccination is associated with reduced severity of community-acquired pneumonia. Eur J Resp Med 2011; 38:147-53.
7. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60.
8. Madhi SA, Adrian P, Kuwanda L, et al. Longterm immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007; 25: 2451-7.
9. Madhi SA, Adrian P, Kuwanda L, Cutland C, Albrich WC, Klugman KP. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization in HIV-Infected and HIV-uninfected children. J Infect Dis 2007; 196: 1662-6.
10. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:155-63.